Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Model Based Approach to Evaluate Isatuximab Monthly Dosing Regimen in Relapsed/Refractory Multiple Myeloma Patients

Hoai-Thu Thai, Nadia Gaudel-Dedieu, Marc Cerou, Bernard Sebastien, Helgi van de Velde, MD PhD, Dorothee Semiond, PhD PharmD, Christine Veyrat-Follet

Blood (2020) 136 (Supplement 1): 44.

https://doi.org/10.1182/blood-2020-139358

Published: 2020

Journal Articles

Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis

Thomas Martin, MD, Joseph Mikhael, MD FRCPC, MD, Roman Hajek, MD, Kihyun Kim, MD PhD, Kenshi Suzuki, MD PhD, Cyrille Hulin, MD, Mamta Garg, MD FRCP, FRCPath, Hang Quach, MDFRACP,FRCPA,MBBS, Hanlon Sia, Anup George, Tatiana Konstantinova, MD PhD, Marie-Laure Risse, Gaelle Asset, Sandrine Macé, Helgi van de Velde, MD PhD, Philippe Moreau, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-137681

Published: 2020

Journal Articles

Development of a Hydrashift 2/4 Isatuximab Assay to Mitigate Interference with Monoclonal Protein Detection on Immunofixation Electrophoresis in Vitro Diagnostic Tests in Multiple Myeloma

Greg Finn, PhD, Sandrine Macé, Ruiyin Chu, Helgi van de Velde, MD PhD, Samia Menad, Marie-Thérèse Melki, PhD, Georges Nouadje

Blood (2020) 136 (Supplement 1): 15.

https://doi.org/10.1182/blood-2020-136613

Published: 2020

Journal Articles

The Relationship between Baseline Biomarkers and Efficacy of Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM: Insights from Phase 1 and Phase 3 Studies

Paul G. Richardson, MD, Joseph Mikhael, MD FRCPC, MD, Thierry Facon, MD, William I. Bensinger, Sandrine Macé, Marielle Chiron, Helgi van de Velde, MD PhD, Frank Campana, MD, Li Liu, Michel Attal, MD PhD

Blood (2019) 134 (Supplement_1): 3179.

https://doi.org/10.1182/blood-2019-128071

Published: 2019

Journal Articles

Depth of Response and Response Kinetics in the Icaria-MM Study of Isatuximab with Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Cyrille Hulin, MD, Paul G. Richardson, MD, Michel Attal, MD PhD, Hugh J. Goodman, FRACP, Vadim A Doronin, MD, Ivan Spicka, MD PhD Prof, Solenn Le-Guennec, Frank Campana, MD, Helgi van de Velde, MD PhD, Meral Beksac, MD

Blood (2019) 134 (Supplement_1): 3185.

https://doi.org/10.1182/blood-2019-129840

Published: 2019

Journal Articles

Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis

Fredrik H. Schjesvold, MD PhD, Paul G. Richardson, MD, Michel Attal, MD PhD, Thierry Facon, MD, Adrián Alegre, MD, Andrew Spencer, DM, Artur Jurczyszyn, MD, Kazutaka Sunami, MD PhD, Laurent Frenzel, MD PhD, Chang-Ki Min, MD PhD, Solenn Le-Guennec, Frank Campana, MD, Helgi van de Velde, MD PhD, Samira Bensfia, MD, Sara Bringhen

Blood (2019) 134 (Supplement_1): 1893.

https://doi.org/10.1182/blood-2019-128010

Published: 2019

Journal Articles

Exposure-Response Analyses and Disease Modeling for Selection and Confirmation of Optimal Dosing Regimen of Isatuximab in Combination Treatment in Patients with Multiple Myeloma

Fatiha Rachedi, Kimiko Koiwai, Nadia Gaudel-Dedieu, Bernard Sebastien, Hoai-Thu Thai, Raouf El-Cheikh, Claire Brillac, Jean Baptiste Fau, Laurent Nguyen, Li Liu, Frank Campana, MD, Helgi van de Velde, MD PhD, Christine Veyrat-Follet, Dorothee Semiond, PhD PharmD

Blood (2019) 134 (Supplement_1): 1897.

https://doi.org/10.1182/blood-2019-128875

Published: 2019

Journal Articles

Evaluating Isatuximab Interference with Monoclonal Protein Detection By Immuno-Capture and Liquid Chromatography Coupled to High Resolution Mass Spectrometry in the Pivotal Phase 3 Multiple Myeloma Trial, Icaria-MM

Greg Finn, PhD, Sandrine Macé, Frank Campana, MD, Solenn Le-Guennec, Stephané Muccio, Alexandra Tavernier, Marie-Claude Rouchon, Alain Roccon, Shujia Dai, Valérie Boutet, Dominique Mouret, Béatrice Pradeilles, Sébastien Hugla, Graziella Engelvin, Deborah DiNoto, Helgi van de Velde, MD PhD, Olivier Fedeli

Blood (2019) 134 (Supplement_1): 3143.

https://doi.org/10.1182/blood-2019-129963

Published: 2019

Journal Articles

Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies

Meletios A. Dimopoulos, Jacob Laubach, MD, Maria Asuncion Echeveste Gutierrez, Norbert Grząśko, Craig C Hofmeister, MDMPH, Jesus F. San Miguel, MD, Shaji K Kumar, MD, Vickie Lu, PhD, Zhaoyang Teng, PhD, Guohui Liu, PhD, Catriona Byrne, RN, Deborah Berg, RN, MSN, Richard Labotka, MD MS, Helgi van de Velde, MD PhD, Paul G Richardson, MD

Blood (2017) 130 (Supplement 1): 902.

https://doi.org/10.1182/blood.V130.Suppl_1.902.902

Published: 2017

Journal Articles

Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2016) 128 (22): 243.

https://doi.org/10.1182/blood.V128.22.243.243

Published: 2016

Journal Articles

Ninlaro (ixazomib) and Brentuximab Vedotin (ADCETRIS) Combination Results in Synergistic Antitumor Activity in Mouse Models of CD30 Positive Anaplastic Large Cell Lymphoma

Nibedita Chattopadhyay, PhD, Sakeena Syed, Yuhong Zhang, Jie Yu, M.S., Dan He McDougall, Lunyin Yu Yu, Stephen Tirrell, PhD, Allison Berger, PhD, Helgi van de Velde, MD PhD, Christopher Tremblay, Dirk Huebner, MD

Blood (2016) 128 (22): 1842.

https://doi.org/10.1182/blood.V128.22.1842.1842

Published: 2016

Journal Articles

Longer Time to Best Response and Depth of Response Are Associated with Improved Duration of Best Achieved Response and Progression-Free Survival (PFS): Post-Hoc Analysis of Phase 3 Tourmaline-MM1 Trial in Relapsed/Refractory Multiple Myeloma (RRMM)

Laurent Garderet, MD PhD, Jacob P. Laubach, MD, Anne-Marie Stoppa, MD, Parameswaran Hari, MD MRCP, MS, Michele Cavo, MD, Heinz Ludwig, MD, Maria-Victoria Mateos, MD PhD, Katarina Luptakova, Jianchang Lin, PhD, Helgi van de Velde, MD PhD, Deborah Berg, RN, MSN, Philippe Moreau, Paul G. Richardson, MD

Blood (2016) 128 (22): 2134.

https://doi.org/10.1182/blood.V128.22.2134.2134

Published: 2016

Journal Articles

Skeletal Muscle Density Is Independently Prognostic of Outcomes in Newly Diagnosed Mantle Cell Lymphoma Patients: Post Hoc Analysis of LYM 3002

Michael P. Chu, MD, Andrew Belch, MD, Lixia Pei, PhD, Xue (Loya) Yang, PhD, Tadeusz Robak, MD PhD, Brendan Rooney, PhD, Andrew Cakana, MD, Helgi van de Velde, MD PhD, Michael B Sawyer, MD

Blood (2015) 126 (23): 1477.

https://doi.org/10.1182/blood.V126.23.1477.1477

Published: 2015

Journal Articles

Efficacy and Safety of Bortezomib Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in Japanese Patients (Pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL) Not Considered for Transplantation Enrolled in the International, Randomized, Phase 3 LYM-3002 Study (NCT00722137)

Michinori Ogura, MD PhD, Lixia Pei, PhD, Brendan Rooney, PhD, Helgi van de Velde, MD PhD, Franco Cavalli, MD for the LYM-3002 investigators

Blood (2014) 124 (21): 3061.

https://doi.org/10.1182/blood.V124.21.3061.3061

Published: 2014

Journal Articles

Efficacy and Safety of Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in a Subset of Newly Diagnosed Mantle Cell Lymphoma (MCL) Patients (Pts) Medically Eligible for Transplantation in the Randomized Phase 3 LYM-3002 Study (NCT00722137)

Johannes Drach, MD, Huiqiang Huang, MD, Olga S Samoilova, MD, Andrew Belch, MD, Charles M. Farber, MD PhD, André Bosly, MD PhD, Jan Novak, MD PhD, Jan Zaucha, MD PhD, Angela Dascalescu, MD PhD, Udomsak Bunworasate, MD, Zvenyslava Masliak, MD PhD, Kateryna Vilchevskaya, MD PhD, Tadeusz Robak, MD, Lixia Pei, PhD, Brendan Rooney, PhD, Helgi van de Velde, MD PhD, Franco Cavalli, MD

Blood (2014) 124 (21): 3064.

https://doi.org/10.1182/blood.V124.21.3064.3064

Published: 2014

Journal Articles

Bortezomib (Btz) Dose Intensity Is the Strongest Predictor for Overall Survival (OS) in Mantle Cell Lymphoma (MCL) Patients (Pts) Not Considered for Transplantation, Receiving Frontline Btz Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Therapy in the Phase 3 LYM-3002 Study

Tadeusz Robak, MD, Huiqiang Huang, MD, Jie Jin, MD, Jun Zhu, MD, Ting Liu, Olga S Samoilova, MD, Halyna Pylypenko, MD, Gregor Verhoef, MD PhD, Noppadol Siritanaratkul, MD, Evgenii A Osmanov, MD PhD, Julia Alexeeva, MD PhD, Juliana Pereira, PhD, Jiri Mayer, Prof., MD PhD, Xiaonan Hong, MD, Yoshiharu Maeda, MD, Lixia Pei, PhD, Brendan Rooney, PhD, Helgi van de Velde, MD PhD, Franco Cavalli, MD

Blood (2014) 124 (21): 4412.

https://doi.org/10.1182/blood.V124.21.4412.4412

Published: 2014

Journal Articles

Superior Restoration of Health with Siltuximab Among Multicentric Castleman’s Disease Patients When Measured By SF-36

Frits van Rhee, MD PhD, Corey Casper, MD, Margaret K Vernon, PhD, Dylan Trundell, MSc, Don Robinson, MSPH, Jianming He, PhD, Jessica Vermeulen, MD PhD, Helgi van de Velde, MD PhD, Raymond S Wong, MD

Blood (2014) 124 (21): 4469.

https://doi.org/10.1182/blood.V124.21.4469.4469

Published: 2014

Journal Articles

Subcutaneous (SQ) Bortezomib (BTZ) in Patients (Pts) with Relapsed Mantle Cell Lymphoma (MCL): Retrospective, Observational Study of Treatment Patterns and Outcomes in US Community Oncology Practices

Alan P Skarbnik, MD, Esprit Ma, MPH, Marie-Hélène Lafeuille, MA, Jonathan Fortier, MA, Tatyana Feldman, MD, Mei Sheng Duh, MPH, ScD, Yvette Ng, MS, MBA, Helgi van de Velde, MD PhD, Edward Dow, MD, Liviu Niculescu, MD, Vijayveer Bonthapally, PhD, Andre Goy, MD MS

Blood (2014) 124 (21): 1740.

https://doi.org/10.1182/blood.V124.21.1740.1740

Published: 2014

Journal Articles

QT Interval Effects and M-Protein Response in a Phase 1 Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) in Patients with Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma.

Sheeba K. Thomas, MD, Alexander Suvorov, MD, Lucien Noens, MD, PhD, Oleg Rukavitsin, MD, Joseph Fay, MD, Ka Lung Wu, MD, PhD, Todd M Zimmerman, MD, Helgi van de Velde, MD, PhD, Rajesh Bandekar, PhD, Thomas A Puchalski, PharmD, Ming Qi, MD, PhD, Clarissa Uhlar, PhD, Olga S Samoilova, MD

Blood (2012) 120 (21): 2972.

https://doi.org/10.1182/blood.V120.21.2972.2972

Published: 2012

Journal Articles

Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study

Blood (2011) 118 (21): 265.

https://doi.org/10.1182/blood.V118.21.265.265

Published: 2011

NARROW

Model Based Approach to Evaluate Isatuximab Monthly Dosing Regimen in Relapsed/Refractory Multiple Myeloma Patients

Depth of Response and Response Kinetics of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Ikema Interim Analysis

Development of a Hydrashift 2/4 Isatuximab Assay to Mitigate Interference with Monoclonal Protein Detection on Immunofixation Electrophoresis in Vitro Diagnostic Tests in Multiple Myeloma

The Relationship between Baseline Biomarkers and Efficacy of Isatuximab in Combination with Pomalidomide and Dexamethasone in RRMM: Insights from Phase 1 and Phase 3 Studies

Depth of Response and Response Kinetics in the Icaria-MM Study of Isatuximab with Pomalidomide/Dexamethasone in Relapsed/Refractory Multiple Myeloma

Efficacy of Isatuximab with Pomalidomide and Dexamethasone in Elderly Patients with Relapsed/Refractory Multiple Myeloma: Icaria-MM Subgroup Analysis

Exposure-Response Analyses and Disease Modeling for Selection and Confirmation of Optimal Dosing Regimen of Isatuximab in Combination Treatment in Patients with Multiple Myeloma

Evaluating Isatuximab Interference with Monoclonal Protein Detection By Immuno-Capture and Liquid Chromatography Coupled to High Resolution Mass Spectrometry in the Pivotal Phase 3 Multiple Myeloma Trial, Icaria-MM

Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies

Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM)

Ninlaro (ixazomib) and Brentuximab Vedotin (ADCETRIS) Combination Results in Synergistic Antitumor Activity in Mouse Models of CD30 Positive Anaplastic Large Cell Lymphoma

Longer Time to Best Response and Depth of Response Are Associated with Improved Duration of Best Achieved Response and Progression-Free Survival (PFS): Post-Hoc Analysis of Phase 3 Tourmaline-MM1 Trial in Relapsed/Refractory Multiple Myeloma (RRMM)

Skeletal Muscle Density Is Independently Prognostic of Outcomes in Newly Diagnosed Mantle Cell Lymphoma Patients: Post Hoc Analysis of LYM 3002

Efficacy and Safety of Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Vs R-CHOP in a Subset of Newly Diagnosed Mantle Cell Lymphoma (MCL) Patients (Pts) Medically Eligible for Transplantation in the Randomized Phase 3 LYM-3002 Study (NCT00722137)

Bortezomib (Btz) Dose Intensity Is the Strongest Predictor for Overall Survival (OS) in Mantle Cell Lymphoma (MCL) Patients (Pts) Not Considered for Transplantation, Receiving Frontline Btz Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) Therapy in the Phase 3 LYM-3002 Study

Superior Restoration of Health with Siltuximab Among Multicentric Castleman’s Disease Patients When Measured By SF-36

Subcutaneous (SQ) Bortezomib (BTZ) in Patients (Pts) with Relapsed Mantle Cell Lymphoma (MCL): Retrospective, Observational Study of Treatment Patterns and Outcomes in US Community Oncology Practices

QT Interval Effects and M-Protein Response in a Phase 1 Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) in Patients with Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma.

Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only